Journal
CANCER LETTERS
Volume 314, Issue 1, Pages 63-72Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2011.09.012
Keywords
Non-small cell lung cancer; Epidermal growth factor receptor; KRAS; MET; Mutation; Gene copy number
Categories
Funding
- National Natural Science Foundation of China [307009 79]
Ask authors/readers for more resources
This study aimed to detect mutations in EGFR and KRAS and alterations of c-Met gene copy number (GCN) changes in primary and lymph node-metastatic NSCLCs. The data showed the concordant rate of EGFR genotype in primary and stage N2 lymph node-metastatic tumors was 95.45%. c-Met GCN in stage N2 lymph nodes was significantly higher than that of the primary tumors (P = 0.038). The results suggest both primary and lymph-node metastases have relatively consistent EGFR mutations and EGFR mutations are not relevant to changes in c-Met GCN. c-Met GCN was increased significantly in EGFR TKI-naive patients with lymph node-metastatic tumors. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available